231 related articles for article (PubMed ID: 17033807)
1. Predictive risk factors for coronary artery abnormalities in Kawasaki disease.
Kim T; Choi W; Woo CW; Choi B; Lee J; Lee K; Son C; Lee J
Eur J Pediatr; 2007 May; 166(5):421-5. PubMed ID: 17033807
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age.
Song D; Yeo Y; Ha K; Jang G; Lee J; Lee K; Son C; Lee J
Eur J Pediatr; 2009 Nov; 168(11):1315-21. PubMed ID: 19159953
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
Hsu CH; Chen MR; Hwang FY; Kao HA; Hung HY; Hsu CH
Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
[TBL] [Abstract][Full Text] [Related]
4. Kawasaki disease in infants less than one year of age.
Rosenfeld EA; Corydon KE; Shulman ST
J Pediatr; 1995 Apr; 126(4):524-9. PubMed ID: 7699529
[TBL] [Abstract][Full Text] [Related]
5. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
[TBL] [Abstract][Full Text] [Related]
6. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
7. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor.
Yeo Y; Kim T; Ha K; Jang G; Lee J; Lee K; Son C; Lee J
Eur J Pediatr; 2009 Feb; 168(2):157-62. PubMed ID: 18478263
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
Terai M; Shulman ST
J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience.
Maric LS; Knezovic I; Papic N; Mise B; Roglic S; Markovinovic L; Tesovic G
Rheumatol Int; 2015 Jun; 35(6):1053-8. PubMed ID: 25429794
[TBL] [Abstract][Full Text] [Related]
10. Low risk of treatment resistance in Down syndrome with Kawasaki disease.
Takatsuki S; Ogata S; Ishii M; Yokozawa M; Ono M; Fujiwara M; Ida H; Motomura H; Moriuchi H; Taketazu M; Kawamura Y; Kawano T; Izumi T; Shiono J; Tsuchiya S; Tsuchiya K; Goushi T; Ichida F; Saji T
Pediatr Int; 2017 Dec; 59(12):1236-1239. PubMed ID: 28960680
[TBL] [Abstract][Full Text] [Related]
11. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of vascular leakage in acute Kawasaki disease.
Terai M; Honda T; Yasukawa K; Higashi K; Hamada H; Kohno Y
Circulation; 2003 Jul; 108(3):325-30. PubMed ID: 12835221
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
Tanaka A; Inoue M; Hoshina T; Koga H
J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
[TBL] [Abstract][Full Text] [Related]
14. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm.
Nomura Y; Masuda K; Yoshinaga M; Sameshima K; Miyata K
Pediatr Int; 2002 Aug; 44(4):353-7. PubMed ID: 12139556
[TBL] [Abstract][Full Text] [Related]
15. Do we have a less severe form of Kawasaki disease or is it the gammaglobulin effect?
Abushaban L; Salama A; Uthaman B; Kumar A; Selvan J
Int J Cardiol; 1999 Apr; 69(1):71-6. PubMed ID: 10362375
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
Jaggi P; Wang W; Dvorchik I; Printz B; Berry E; Kovalchin JP; Texter K; Ramilo O; Burns JC; Tremoulet AH
Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
[TBL] [Abstract][Full Text] [Related]
17. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
[TBL] [Abstract][Full Text] [Related]
18. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
19. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
[TBL] [Abstract][Full Text] [Related]
20. The Harada score in the US population of children with Kawasaki disease.
Tewelde H; Yoon J; Van Ittersum W; Worley S; Preminger T; Goldfarb J
Hosp Pediatr; 2014 Jul; 4(4):233-8. PubMed ID: 24986993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
